T
TELO
vs
S&P 500
S&P 500
Over the past 12 months, TELO has underperformed S&P 500, delivering a return of -74% compared to the S&P 500's +12% growth.
Stocks Performance
TELO vs S&P 500
Performance Gap
TELO vs S&P 500
Performance By Year
TELO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Telomir Pharmaceuticals Inc
Glance View
Telomir Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The company went IPO on 2024-02-09. Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The firm is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. TELOMIR-1 serve as a metal enzyme inhibitor of essential metals such as zinc and copper. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The Company’s BioMAP platform provides an unbiased, target-agnostic, and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers.
